Innate Pharma S.a Stock Earnings Reports

Innate Pharma is focused on three prioritized oncology programs: lacutamab (CTCL), IPH4502 (next-generation Nectin-4 ADC), and monalizumab (co-developed with AstraZeneca). Key near-term clinical and corporate priorities include initiating the TELLOMAK-3 Phase III confirmatory trial for lacutamab in the second half of 2026 (with potential accelerated approval pathway in Sezary syndrome), advancing IPH4502 through a Phase I dose-escalation/enrichment with early signs of antitumor activity including in post-enfortumab vedotin (EV) urothelial cancer, and awaiting the PACIFIC-9 Phase III readout for monalizumab in NSCLC in H2 2026. The company is pursuing non-dilutive financing options (partnering or royalty structures) to support late-stage development and has streamlined the organization, completing a workforce restructuring plan. Financially, 2025 revenue was EUR 9M, operating expenses EUR 63M (73% R&D), R&D spend fell 16% YoY to EUR 43.6M, and cash was EUR 44.8M at year-end—providing runway into Q3 2026 under the current plan. Partnerships with AstraZeneca (monalizumab, IPH5201) include substantial milestone and royalty/profit-share arrangements that represent potential upside if programs advance. Commercial strategy for lacutamab emphasizes a targeted launch in Sezary syndrome (concentrated treatment at ~50 U.S. centers) with an addressable expansion into Mycosis Fungoides and broader CTCL over time.